Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 3Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 12Carcinoma, Non-Small-Cell Lung 10Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Stomach Neoplasms 2Recurrence 2Head and Neck Neoplasms 2HER2-positive Breast Cancer 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Squamous Cell Non-small Cell Lung Cancer 1Small Cell Lung Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Gastroesophageal Junction Cancer 1Esophageal Neoplasms 1Carcinoma, Squamous Cell 1Advanced or Metastatic Squamous Non-Small Cell Lung Cancer 1Advanced Solid Tumors 1Advanced Pancreatic Cancer 1Advanced Non-small Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1Advanced Malignant Neoplasm 1Advanced Esophageal Carcinoma 1Advanced Breast Cancer 1

Interventions

fludarabine 1Interleukin-2 1Docetaxel 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Advanced Non-Small Cell Lung Cancer × Docetaxel × Clear all
NCT05910034 2023-06-18

Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC

Fudan University

Phase 2 Not yet recruiting
132 enrolled
Thoracic

Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡